BPC-157 vs GHK-Cu
BPC-157 (Synthetic pentadecapeptide) and GHK-Cu (Copper-binding tripeptide) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | BPC-157 | GHK-Cu |
|---|---|---|
| Compound class | Synthetic pentadecapeptide | Copper-binding tripeptide |
| Research category | Healing & Recovery | Cosmetic & Dermal |
| Length (amino acids) | 15 amino acids | 3 amino acids |
| Molecular weight | 1419.5 Da | 340.4 Da |
| Half-life | <30 minutes (elimination, reported in rats/dogs) | Not documented |
| Origin | BPC-157 is a synthetic peptide whose sequence corresponds to a partial fragment of human body protection compound (BPC), a protein reported to be present in gastric juice. It does not occur naturally as an isolated peptide and is produced synthetically for research. | GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, with levels reported to decline with age. GHK-Cu is its complex with copper(II) ions and is widely used as a cosmetic ingredient. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How BPC-157 works
In animal and in-vitro studies, BPC-157 has been associated with promotion of angiogenesis and modulation of growth-factor signaling pathways, including effects reported on the VEGFR2 pathway and nitric oxide systems. Researchers have also described interactions with the FAK-paxillin pathway and effects on fibroblast and tendon-cell migration. These mechanisms are characterized primarily in rodent models and cell culture and have not been established in controlled human trials.
How GHK-Cu works
GHK has a high affinity for copper(II) and is understood to act partly as a copper-delivery molecule, facilitating copper transport relevant to enzymatic and remodeling processes. In cell and skin research it has been associated with signaling that influences extracellular-matrix remodeling, collagen and glycosaminoglycan synthesis, and antioxidant and gene-expression effects. Much of this work is from in-vitro and skin studies.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
BPC-157
GHK-Cu
What sets each apart
BPC-157
Unlike copper-binding cosmetic tripeptides or the actin-modulating TB-500, BPC-157 is a longer synthetic peptide studied primarily for connective-tissue and gastrointestinal repair endpoints in animals.
GHK-Cu
GHK-Cu is the most established copper tripeptide in cosmetic use, distinguished from AHK-Cu by its sequence and from repair peptides like BPC-157 by its remodeling and copper-delivery focus.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is BPC-157 and what class of peptide is it?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids derived from a partial sequence of a protein found in human gastric juice. It is studied in the research literature as a cytoprotective and tissue-repair agent, not as an approved drug. It has no established endogenous receptor and its mechanisms are still under active investigation.
What is BPC-157 studied for in the research literature?
In animal models, BPC-157 has been researched in the context of tendon, ligament, muscle, and bone healing, gastrointestinal mucosal protection, and angiogenesis. Much of the work implicates nitric oxide pathways and upregulation of growth-factor and angiogenic signaling. To date these findings are almost entirely preclinical, and no human clinical efficacy has been established.
Why is BPC-157's short half-life not reflected in dosing frequency?
Pharmacokinetic work in rats and dogs reports an elimination half-life under about 30 minutes, yet most rodent studies use once-daily dosing. This is often described as a PK/PD disconnect: the downstream biological effects the peptide triggers persist well beyond the peptide's own residence time. Researchers therefore design protocols around effect duration rather than plasma half-life.
What is GHK-Cu?
GHK-Cu is a complex of the naturally occurring tripeptide GHK (glycyl-L-histidyl-L-lysine) with a copper(II) ion. The GHK sequence is a subfragment of the alpha-2 chain of type I collagen and is present in human plasma, where its level declines with age. It is studied primarily as a copper-delivery and skin-remodeling signal peptide.
What is GHK-Cu studied for?
In research and cosmetic-formulation literature it is studied for collagen and glycosaminoglycan synthesis in dermal fibroblasts, wound-model remodeling, and antioxidant/gene-modulating activity. It is characterized as a signaling peptide rather than a therapeutic drug, and is not FDA-approved for treating any condition.
Why is a higher GHK-Cu concentration not necessarily better?
Research summaries note a biphasic dose response: GHK-Cu stimulates matrix synthesis at low (picomolar to nanomolar) concentrations, but at higher concentrations it can also upregulate matrix-degrading enzymes. This is why most cosmetic formulation guidance centers on the low end of the topical range rather than maximizing concentration.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.